# RVU120 Rollover Study

> **NCT06987058** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ryvu Therapeutics SA** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Acute Myeloid Leukaemia (AML)
- High-risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** RVU120

## Key facts

- **NCT ID:** NCT06987058
- **Lead sponsor:** Ryvu Therapeutics SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987058, "RVU120 Rollover Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06987058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*